LENSAR, Inc. (LNSR) News
Filter LNSR News Items
LNSR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
LNSR News Highlights
- LNSR's 30 day story count now stands at 2.
- Over the past 5 days, the trend for LNSR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest LNSR News From Around the Web
Below are the latest news stories about LENSAR INC that investors may wish to consider to help them evaluate LNSR as an investment opportunity.
LENSAR Reports First Quarter 2023 Results and Provides Business UpdateORLANDO, Fla., May 15, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2023 and provided an update on key operational initiatives. |
LENSAR to Report First Quarter 2023 Financial Results on Monday, May 15, 2023ORLANDO, Fla., May 10, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s first quarter 2023 financial results will be released before market open on Monday, May 15, 2023. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Monday, May 15, 2023 to discuss the financial results and recent corporate high |
LENSAR, Inc. (NASDAQ:LNSR) Q4 2022 Earnings Call TranscriptLENSAR, Inc. (NASDAQ:LNSR) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good morning, and thank you for your participation. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. As a reminder, this conference call will be recorded. I would now like to turn the conference over […] |
LENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateORLANDO, Fla., March 16, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2022 and provided an update on key operational initiatives. |
LENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023ORLANDO, Fla., March 09, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2022 financial results will be released before market open on Thursday, March 16, 2023. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Thursday, March 16, 2023 to discuss the financial results |
LENSAR Announces Preliminary Fourth Quarter and Full Year 2022 ResultsORLANDO, Fla., February 14, 2023--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022 and its cash balance as of December 31, 2022, and provided an update on the launch of its ALLY® Adaptive Cataract Treatment System. |
LENSAR to Present at Two Upcoming Investor ConferencesORLANDO, Fla., November 22, 2022--LENSAR, Inc. (NASDAQ: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer will present at two upcoming investor conferences: |
LENSAR Reports Third Quarter 2022 Financial Results and Provides Business UpdateORLANDO, Fla., November 09, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2022 and provided a business update. |
LENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022ORLANDO, Fla., November 02, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s third quarter 2022 financial results will be released before market open on Wednesday, November 9, 2022. LENSAR’s management will host a conference call and webcast at 8:30 am ET on Wednesday, November 9, 2022 to discuss the financial results and re |
LENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EUORLANDO, Fla., September 08, 2022--LENSAR, Inc. (Nasdaq: LNSR) ("LENSAR" or "the Company"), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced the application for certification of the ALLY™ Adaptive Cataract Treatment System ("ALLY" or the "ALLY System") in the European Union. |